China God group targeted to raise 275 million investment four projects

The actual control person has just changed the Hua Shen Group (000790) announced the Non-public offering plan today, the company intends to raise not more than 275 million yuan cash investment in 4 main business related projects. Under the Non-public offering program of the group, the company will issue no more than 32 million shares to no more than 10 specific objects and the issue price shall not be less than 8.92 yuan/share.　　The fund-raising projects include the technical renovation and expansion of the Hua Shen Group pharmaceutical company, the new drug Research and development project, the Licatin and Deep Research project, the Biotechnology Extension project and the 37 planting base construction and reserve project, the total investment is about 275 million yuan, and the total amount of funds raised does not exceed the total invested capital. It is reported that the largest investment in the investment project is the Hua Shen Group of pharmaceutical technical renovation and expansion and new drug research and development projects, the project has invested a total of 135 million yuan. Among them, infrastructure construction investment 120 million yuan, three kinds of new drug related research total input 15 million yuan.　　The three research projects were three phases clinical study of Wulong granules, two phase, three phase clinical study and 37 Tong Shu capsules. Data show that the Hua Shen Group Pharmaceutical Factory is a subsidiary of the Chinese god Group, mainly for the mixture, capsules, granules, tablets, moxibustion, dry suspension, raw materials production, the main products have nasal yuan Shu oral liquid/capsule, Vitality su oral liquid, 37 Tong Shu capsules.　　The above project will be in the Chengdu Hi-tech Development Zone Huatian High-tech Industrial Park to carry out technical transformation, the project is completed, the annual treatment of Chinese herbal medicines 4500 tons, annual output of 100 million tablets, an annual output of 800 million capsules, an annual output of 100 million bag granules, an annual output of 75 million oral liquid production capacity. A wide range of external attention to the treatment of liver cancer drugs Licatin will also implement technical expansion and in-depth research projects. The project is to renew and transform the Lee Ting production line in the hi-Tech industrial Park of Chengdu Hi-tech Development zone at the same time, two new product lines were created, namely, the recombinant human epidermal growth factor (Ai Ying) production line and oxidized low density lipoprotein (LDL) production line were used to study the clinical efficacy of Licatin.　　The project is built up to postpartum, the company produces Licatin 15,000, Ai Ying 2 million and kit 200,000 boxes each year. It is noteworthy that Hua Shen Group has previously announced that Shanghai Hua-min Investment Management Co., Ltd. May 13 with Shanghai Tong Gong Investment Co., Ltd., Shanghai Woo-Chang Industrial Co., Ltd. signed the "Equity transfer Agreement", the two companies held by the Chinese god Group, the controlling shareholder of the group of 45.69% of China, Sichuan, China Become the largest shareholder of the Chinese God of Sichuan. As a result, huamin, the head of the department Li Xiaomin became the real control of the group.